SERCA Targeting Pharmaceuticals
A link has been found between a variety of heart and bone illnesses and the dysregulation of sarco/endoplasmic reticulum calcium ATPase (SERCA), the calcium pump in cardiac and skeletal muscles. To test pharmaceuticals aimed at treating and reversing the diseases caused by impaired SERCA regulations, specific assays must be designed. These tests are required to analyze the reactions between SERCA and emerging drugs, while optimizing efficiency to create quick, reliable, cost effective assays.
Förster Resonance Energy Transfer
A high-throughput assay method has been developed to detect compounds that interact favorably with SERCA. Using Förster resonance energy transfer (FRET), this assay is able to monitor the interactions between pharmaceutical molecules and SERCA acceptor proteins. FRET relied upon fluorescent decan in donor and acceptor proteins, offering high throughput and advanced reliability in discerning small changes in samples. This approach is less susceptible to complicating interferences and is able to provide data that has fewer false positives than previous methods. FRET-based assays to find compounds that favorably interact with SERCA will be a reliable and profitable tool in researching emerging drugs.
BENEFITS AND FEATURES OF SERCA ASSAY:
- Able to quickly and reliably test compounds intended to interact favorably with SERCA
- Reliable testing returns the optimal acceptor protein with fewer errors
- Provides large amounts of raw data that can be analyzed to return applicable information
Phase of Development Study Results Available